Technology
Health
Pharmaceutical

Odonate Therapeutics

$20.60
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.34 (-1.61%) Today
-$0.34 (-1.61%) Today

Why Robinhood?

You can buy or sell ODT and other stocks, options, ETFs, and crypto commission-free!

About

Odonate Therapeutics, Inc. Common Stock, also called Odonate Therapeutics, is a pharmaceutical company, which engages in the development of therapeutics that improves and extends the lives of patients with cancer. Read More It focuses on the development of tesetaxel, a novel chemotherapy agent that belongs to a class of drugs known as taxanes, which are used in the treatment of cancer. The company was founded in March 2013 and is headquartered in San Diego, CA.

Employees
130
Headquarters
San Diego, California
Founded
2013
Market Cap
560.09M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
53.28K
High Today
$21.22
Low Today
$20.52
Open Price
$21.05
Volume
2.42K
52 Week High
$28.57
52 Week Low
$11.54

Collections

Technology
Health
Pharmaceutical
Therapy
Cancer Prevention
2017 IPO
US
North America

News

Guru FocusMar 11

Odonate Therapeutics Inc (ODT) CEO Kevin C Tang Bought $2.6 million of Shares

CEO of Odonate Therapeutics Inc (NASDAQ:ODT) Kevin C Tang bought 140,000 shares of ODT on 03/08/2019 at an average price of $18.26 a share.

48
Simply Wall StMar 8

Did Changing Sentiment Drive Odonate Therapeutics’s (NASDAQ:ODT) Share Price Down By 40%?

Odonate Therapeutics, Inc. (NASDAQ:ODT) shareholders should be happy to see the share price up 16% in the last quarter. But that is minimal compensation for the share price under-performance over the last year. In fact the stock is down 40% in the last year, well below the market return. View our latest analysis for Odonate Therapeutics Odonate Therapeutics hasn’t yet reported any revenue yet, so it’s as much a business idea as a business. We can’t help wondering why it’s publicly listed so early in its j...

14
BusinessWireMar 6

Odonate Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference

SAN DIEGO--(BUSINESS WIRE)--Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, will present at the Cowen and Company 39th Annual Health Care Conference on Wednesday, March 13, 2019, at 8:40 a.m. Eastern Time. About Odonate Therapeutics, Inc. Odonate Therapeutics, Inc. is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and ext...

3

Earnings

-$1.17
-$1.04
-$0.92
-$0.79
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 2, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.